Why the study?
Although SGLT2 inhibitors are recognized for their cardiovascular benefits, their impact on heart failure outcomes in cancer patients and survivors required systematic evaluation.
Do SGLT2 inhibitors reduce heart failure hospitalization and new heart failure diagnoses in cancer patients and survivors?
Do SGLT2 inhibitors reduce heart failure hospitalization and new heart failure diagnoses in cancer patients and survivors?
SGLT2 inhibitors significantly reduce the risk of heart failure hospitalization and new heart failure diagnoses in cancer patients and survivors, with pronounced benefits in breast cancer patients receiving anthracyclines.
Answers are grounded in this paper and cite their sources.
Supports SGLT2i use to cut HF events in cancer patients; extends RCT evidence to cardio-oncology populations.
AIMS: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) are recognized for their cardiovascular benefits. This systematic review and meta-analysis evaluated the impact of SGLT2i on heart failure (HF) outcomes in cancer patients and survivors, focusing on HF hospitalization and new HF diagnoses. METHODS AND RESULTS: A comprehensive search of PubMed, MEDLINE, and Embase via Ovid, and the Cochrane Library was conducted up to 5 June 2024, focusing on studies involving cancer patients and survivors treated with SGLT2i. The search criterion used was [(SGLT2) OR (Sodium glucose cotransporter 2 inhibitors) OR (canagliflozin) OR (dapagliflozin) OR (empagliflozin) OR (ertugliflozin) AND (cancer)]. The primary outcomes assessed were HF hospitalization and new HF diagnoses. The search yielded 1880 studies, from which 13 studies encompassing 88 273 patients were included. SGLT2i use reduced HF hospitalizations by 51% (RR 0.49, 95% CI 0.36-0.66, I² = 28%, P < 0.01) and new HF diagnoses by 71% (RR 0.29, 95% CI 0.10-0.87, I² = 71%). Multi-variate meta-regression analysis suggested that among breast cancer populations, studies with ≥50% of patients on anthracyclines exhibited a 99% reduction in HF hospitalization risk compared with similar studies that included <50% of patients on anthracyclines (RR 0.0085, 95% CI: 0.0001-0.2645, P = 0.0081). CONCLUSION: SGLT2i significantly lower the risk of HF hospitalization and new HF diagnoses among cancer patients and survivors, with particularly pronounced benefits in breast cancer patients receiving anthracycline-based chemotherapy. These findings support the need for prospective trials to further investigate the integration of SGLT2i into cancer patient management to enhance cardiovascular outcomes.
No takes yet. Share an insight, caveat, or question.
Bhalraam et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: